Compounded Semaglutide and Tirzepatide Top 1,700 Federal Problem Reports

What Happened

Adverse event reports tied to compounded GLP-1 medicines have passed 1,700 in federal databases, according to data released by the US Food and Drug Administration — a milestone that lands amid the agency's most aggressive enforcement stretch against compounders and unapproved sellers in a decade.

As of the end of May 2026, the FDA had received 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. The agency notes these figures are almost certainly undercounted, because state-licensed pharmacies outside the outsourcing-facility system are not required to report adverse events to the FDA at all.

Among the reports are hospitalizations potentially linked to dosing errors with compounded injectable semaglutide, and cases involving compounded products supplied outside the approved-label strength range — a recurring failure mode of hand-filled vials that the agency has flagged repeatedly.

Who Is Affected

• Patients who obtained compounded GLP-1 injections through telehealth platforms and clinics during and after the shortage era.
• Prescribers and pharmacists, who face intensifying liability as the FDA moves to shut down bulk compounding of the three most in-demand GLP-1s.
• Researchers, whose peptide supply chains sit adjacent to the same gray market the FDA is dismantling.

Timeline

• 2023-2024 — GLP-1 shortages push millions of doses into pharmacy compounding channels.
• 2024-2025 — The FDA resolves shortage declarations for semaglutide and tirzepatide and begins winding down compounding flexibility.
• April 2026 — The FDA proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list after finding no clinical need for bulk compounding; a facility is cited for sterility failures.
• May 2026 onward — Problem reports cross 1,700. In the preceding months, roughly 30 warning letters hit telehealth companies over misleading claims — part of what the agency described as more enforcement activity in six months than in the prior decade.
• Ongoing — A secret-shopper study published in JAMA Health Forum finds some clinics reformulating products with added ingredients to sidestep the copying ban.

What This Means for Researchers

The 1,700-report threshold is a quality signal, not just a statistic. The failure patterns federal reviewers describe — mislabeled concentration, inconsistent fill volume, non-sterile handling — are exactly the risks laboratory buyers face when they purchase GLP-1 peptides from sellers who also serve the consumer market. When a product's mass-market demand collapses into research channels, quality control rarely improves on the way through.

How to Verify Your Peptides

• The semaglutide purity testing guide and tirzepatide HPLC testing guide detail how reference-standard testing confirms identity and content.
• Our identity, purity, and fill-weight explainer shows why a single-pass lab report is not enough.
• Start with how testing works if you are new to third-party verification.

Safe Alternatives

• Evidence-ranked profiles for semaglutide, tirzepatide, and liraglutide separate approved medicines from research-only analogues.
• Our vendor directory tracks which suppliers publish current, batch-specific analytical results.

Sources

• Regulatory announcements from the US Food and Drug Administration
• Industry reports and peer-reviewed analyses